iX Biopharma, through its wholly-owned subsidiary iX Syrinx, has entered into an agreement with medicinal cannabis company Organic Genetics Group to supply its novel sublingual medicinal cannabis wafers in New Zealand.

The agreement will allow iX Biopharma to access New Zealand’s pharmaceutical market through Organic Genetics Group’s commercial partnership with its shareholder, ANZ Pharma.

ANZ Pharma is a reseller of leading pharmaceutical, health and beauty care products with a distribution network of 1,108 pharmacies.


To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Related Stories

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook